Mark D. Morelli
Mark D. Morelli's purchase track record
Mark D. Morelli has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/4/2022 | VNT | $35K | +34.5% | +56.8% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Vontier Unveils Mobility Platform, Expands Food Aid Program. Vontier announced the launch of Vantage Point, a new platform that aggregates mobility data to help businesses optimize transportation. The company also extended its partnership with the NACS Foundation’s Neighborhood Nourish Program, aiming to address food insecurity in communities. Analysts have highlighted the company’s solid fundamentals and noted potential upside, reflecting growing confidence in its strategic initiatives.
Transaction History
| XYL | ▲ Buy | Grant | 1,711 | $200K | 5/14/2026 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 14,998 | $614K | 2/27/2026 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 10,181 | $418K | 2/19/2026 | View on chart |
| VNT | ▲ Buy | Grant | 61,960 | $0 | 2/16/2026 | View on chart |
| VNT | ▲ Buy | Grant | 40,623 | $0 | 2/16/2026 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 8,679 | $363K | 2/13/2026 | View on chart |
| XYL | ▲ Buy | Grant | 1,300 | $165K | 5/13/2025 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 27,353 | $1.0M | 2/28/2025 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 7,871 | $304K | 2/20/2025 | View on chart |
| VNT | ▲ Buy | Grant | 62,695 | $0 | 2/20/2025 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 10,265 | $414K | 2/19/2025 | View on chart |
| XYL | ▲ Buy | Grant | 1,156 | $0 | 5/16/2024 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 29,013 | $1.2M | 2/28/2024 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 9,423 | $402K | 2/23/2024 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 8,361 | $344K | 2/20/2024 | View on chart |
| VNT | ▲ Buy | Grant | 74,145 | $0 | 2/19/2024 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 19,931 | $691K | 1/25/2024 | View on chart |
| VNT | ▲ Buy | Grant | 45,067 | $0 | 1/25/2024 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 1,996 | $70K | 12/15/2023 | View on chart |
| XYL | ▲ Buy | Grant | 1,580 | $0 | 5/18/2023 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 13,071 | $342K | 2/28/2023 | View on chart |
| VNT | ▲ Buy | Grant | 109,320 | $0 | 2/28/2023 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 9,477 | $246K | 2/24/2023 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 21,394 | $559K | 2/17/2023 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 2,007 | $38K | 12/15/2022 | View on chart |
| VNT | ▲ Buy | Open Market | 2,000 | $35K | 11/4/2022 | View on chart |
| XYL | ▲ Buy | Grant | 1,812 | $0 | 5/12/2022 | View on chart |
| VNT | ▲ Buy | Grant | 11,290 | $271K | 2/28/2022 | View on chart |
| VNT | ▲ Buy | Grant | 88,715 | $0 | 2/28/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 9,528 | $231K | 2/25/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 21,162 | $518K | 2/18/2022 | View on chart |
| XYL | ▲ Buy | Grant | 420 | $0 | 2/14/2022 | View on chart |
| VNT | ▼ Sell | Tax Withholding | 2,019 | $62K | 12/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xylem sees broad analyst price target cuts
Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.
Xylem sees broad analyst price target cuts. Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.